The DOI matches its Crossref record; 567 of the 570 references it cites were found in a registry or an index.
Antifungal Drugs TDM: Trends and Update
Abstract
Purpose: The increasing burden of invasive fungal infections results in growing challenges to antifungal (AF) therapeutic drug monitoring (TDM). This review aims to provide an overview of recent advances in AF TDM. Methods: We conducted a PubMed search for articles during 2016–2020 using “TDM” or “pharmacokinetics” or “drug-drug-interaction” with “antifungal,” consolidated for each AF. Selection was limited to English language articles with human data on drug exposure. Results: More than 1000 articles matched the search terms. We selected 566 publications. The latest findings tend to confirm previous observations in real-life clinical settings. The pharmacokinetic variability related to special populations is not specific but must be considered. AF benefit-to-risk ratio, drug–drug interaction (DDI) profiles, and minimal inhibitory concentrations for pathogens must be known to manage at-risk situations and patients. Itraconazole has replaced ketoconazole in healthy volunteers DDI studies. Physiologically based pharmacokinetic modeling is widely used to assess metabolic azole DDI. AF prophylactic use was studied more for Aspergillus spp. and Mucorales in oncohematology and solid organ transplantation than for Candida (already studied). Emergence of central nervous system infection and severe infections in immunocompetent individuals both merit special attention. TDM is more challenging for azoles than amphotericin B and echinocandins. Fewer TDM requirements exist for fluconazole and isavuconazole (ISZ); however, ISZ is frequently used in clinical situations in which TDM is recommended. Voriconazole remains the most challenging of the AF, with toxicity limiting high-dose treatments. Moreover, alternative treatments (posaconazole tablets, ISZ) are now available. Conclusions: TDM seems to be crucial for curative and/or long-term maintenance treatment in highly variable patients. TDM poses fewer cost issues than the drugs themselves or subsequent treatment issues. The integration of clinical pharmacology into multidisciplinary management is now increasingly seen as a part of patient care.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-therapeutic drug levels are most common with the triazole antifungals despite adherence to recommended dosing regimens.86”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [86]
Citations
Cites
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Worldwide emergence of resistance to antifungal drugs challenges human health and food security
Fisher, M. C., Hawkins, N. J., Sanglard, D., & Gurr, S. J. (2018) · Science · doi:10.1126/science.aap7999 · Cited by 1,555
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#
Abdul-Aziz, M. H., Alffenaar, J.-W. C., Bassetti, M., Bracht, H., Dimopoulos, G., Marriott, D., Neely, M. N., Paiva, J.-A., Pea, F., Sjovall, F., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-06050-1 · Cited by 1,081
The global problem of antifungal resistance: prevalence, mechanisms, and management
Perlin, D. S., Rautemaa-Richardson, R., & Alastruey-Izquierdo, A. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30316-x · Cited by 1,055
Koehler, P., Bassetti, M., Chakrabarti, A., Chen, S. C. A., Colombo, A. L., Hoenigl, M., Klimko, N., Lass-Flörl, C., Oladele, R. O., Vinh, D. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30847-1 · Cited by 951
Chowdhary, A., Sharma, C., & Meis, J. F. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006290 · Cited by 750
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Tissot, F., Agrawal, S., Pagano, L., Petrikkos, G., Groll, A. H., Skiada, A., Lass-Flörl, C., Calandra, T., Viscoli, C., & Herbrecht, R. (2017) · Haematologica · doi:10.3324/haematol.2016.152900 · Cited by 682
Itraconazole resistance in Aspergillus fumigatus
Denning, D. W., Venkateswarlu, K., Oakley, K. L., Anderson, M. J., Manning, N. J., Stevens, D. A., Warnock, D. W., & Kelly, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1364 · Cited by 508
Moriyama, B., Obeng, A. O., Barbarino, J., Penzak, Sr., Henning, S., Scott, S., Agúndez, J., Wingard, Jr., McLeod, H., Klein, T., et al. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.583 · Cited by 404
Research works printed but not linked: 1
- Zhou, 2019, Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling, Eur J Pharm Sci, 139, 105061, 10.1016/j.ejps.2019.105061 · DOI
Cited by
Model-informed precision dosing: State of the art and future perspectives
Minichmayr, I. K., Dreesen, E., Centanni, M., Wang, Z., Hoffert, Y., Friberg, L. E., & Wicha, S. G. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115421 · Cited by 203
“Trends of antifungal TDM have been thoroughly detailed elsewhere [128].”
McCreary, E. K., Davis, M. R., Narayanan, N., Andes, D. R., Cattaneo, D., Christian, R., Lewis, R. E., Watt, K., Wiederhold, N. P., & Johnson, M. D. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2850 · Cited by 113
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
“86 As such, therapeutic drug monitoring, especially for itraconazole, voriconazole and posaconazole, is recommended even in the setting of antifungal prophylaxis.”
BackgroundOverview of therapeutic drug monitoring and clinical practice
Fang, Z., Zhang, H., Guo, J., & Guo, J. (2023) · Talanta · doi:10.1016/j.talanta.2023.124996 · Cited by 100
Baden, L. R., Swaminathan, S., Almyroudis, N. G., Angarone, M., Baluch, A., Barros, N., Buss, B., Cohen, S. H., Cooper, B., Chiang, A. D., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0056 · Cited by 121
“Fluconazole and isavu-conazonium sulfate are the 2 triazoles that do not require TDM. Fluconazole has linear pharmacokinetics that eliminate the need for TDM, 41 – 45 though patients in renal failure should receive a modi fi eddose.”
Metadata
- Authors
- Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M.
- Affiliations
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Faculté de Médecine, Université de Paris, Paris, France;
- Corresponding author
- Kably, Benjamin
- Derobertmasure, Audrey
- Billaud, Eliane M.
- Venue
- Therapeutic Drug Monitoring
- Published
- 2022-02
- Volume
- 44
- Issue
- 1
- Pages
- 166-197
- ISSN
- 0163-4356 (ISSN-L)
- OpenAlex
- W4200470547
- Semantic Scholar
- 4c1d1648909565b264dcdec56d9e4a57f5be99c5
- Cited by
- 81
- References
- 570
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 23 · 2023: 17 · 2022: 5
- FWCI
- 1.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Therapeutic Drug Monitoring (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- antifungal agents, invasive fungal infections, drug-drug interactions, azole antifungals, voriconazole, isavuconazole, fluconazole, amphotericin B, echinocandins, posaconazole, pharmacokinetics, antifungal prophylaxis, Aspergillus, Mucorales, Candida, central nervous system fungal infection, immunocompetent patient, physiologically based pharmacokinetic modeling
- MeSH terms
- Antifungal Agents, Humans, Fluconazole, Drug Monitoring, Itraconazole, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal Drugs TDM: Trends and Update. https://app.cochat.ai/papers/10.1097/ftd.0000000000000952
- The paper
- Kably, B., Launay, M., Derobertmasure, A., Lefeuvre, S., Dannaoui, E., & Billaud, E. M. (2022). Antifungal Drugs TDM: Trends and Update. Therapeutic Drug Monitoring. https://doi.org/10.1097/ftd.0000000000000952
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.